XEP527 for Schizophrenia
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia.
Are You a Good Fit for This Trial?
This trial is for adults aged 18-65 with a confirmed diagnosis of stable schizophrenia, who have been on the same antipsychotic medication (and any other psychiatric meds) at a steady dose for at least 12 weeks. Participants must agree to stay in the hospital for about a month during the study.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- XEP527
Trial Overview
The study is testing XEP527 compared to a placebo in people with stable schizophrenia, while they continue their usual antipsychotic treatment. The main goal is to see if XEP527 is safe and well-tolerated.
How Is the Trial Designed?
6
Treatment groups
Experimental Treatment
Placebo Group
Cohort 3: Dose Level 3 XEP527
Cohort 2: Dose Level 2 XEP527
Cohort 1: Dose Level 1 XEP527
Placebo
Placebo
Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.